Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Nov 26, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.072o, Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Nov 26, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A Medicare Advantage policy for Bevacizumab (Avastin®) and related biosimilars for oncologic use has been reissued. This is a fresh update to existing coverage guidelines that may affect prior authorization, coverage criteria, or billing requirements for cancer treatment medications.

Action Required

Action needed

By November 26, 2025: Billing team must review the updated Bevacizumab (Avastin®) policy at the provided URL to identify any changes to prior authorization requirements, coverage criteria, or billing procedures for oncology patients. Update billing system and encounter forms accordingly for Medicare Advantage plans.

Related policy hubs

Independence Blue Cross policies Oncology Hematology